There is growing interest in the potential of magic mushrooms as a tool for managing a variety of mental health disorders, particularly depression. A popular approach involves regular consumption of about 25 mg of the active ingredient, available for purchase from a mushroom dispensary. This dosage seems to provide relief and could complement traditional depression therapies.
A group of academic researchers found that psilocybin, the active compound in magic mushrooms, demonstrated promising results in the treatment of depression.
Key Points:
- Symptoms of depression can show improvement just eight days after using psilocybin.
- Side effects of psilocybin are usually mild to moderate and are generally well-tolerated.
- A dose of 25mg psilocybin can lead to changes in perception, mood enhancements, increased creativity, and a sense of unity.
One Dose Could Be Sufficient
A recent study employed a rigorous methodology, using a randomized, multi-blinded design to compare a single dose of psilocybin with an active placebo (niacin). The research evaluated the onset, benefits duration, and safety profile of psilocybin over a six-week period.
Study Participants
The study targeted individuals aged 21 to 65 who met the Major Depressive Disorder (MDD) criteria as specified in the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) and were in the midst of a depressive episode lasting at least 60 days at the time.
Study Procedure
Participants were administered either a single 25-mg oral dose of psilocybin or a 100-mg dose of niacin. Niacin was used as an active placebo, causing a quick physiological response (flushing) designed to maintain the blinding integrity.
The psilocybin and niacin placebo were given following a standard “set and setting” protocol. The preparatory sessions, conducted with two facilitators, lasted between 6 and
The dosing session was conducted in a relaxed atmosphere, lasting between 7 to 10 hours. Four hours after the dosage, participants were urged to contemplate their experiences.
Research Findings
Just eight days after receiving the psilocybin dose, participants showed significant signs of reduced depression. This beneficial effect remained stable throughout the six-week monitoring period. According to the Montgomery-Asberg Depression Rating Scale (MADRS), the response and remission rates were higher compared to other psilocybin studies on Treatment-Resistant Depression.
When compared to niacin, psilocybin was found to be more effective in improving psychosocial functioning. It showed potential in various aspects, such as reducing disease severity, anxiety, self-reported depressive symptoms, and enhancing overall quality of life.
The majority of participants tolerated the compound well, with minor to moderate side effects mainly experienced during the first dose. Nevertheless, the treatment with psilocybin had more frequent and severe side effects than niacin, consistent with our existing understanding of its impact.
The researchers noted that psychedelics like psilocybin could cause side effects that standard rating scales may not always capture, or they could reveal previously undetected psychiatric conditions, even while effectively treating specific disorders.
Understanding a 25-mg Dose
A standard psychedelic dose of psilocybin is between 15 to 25 milligrams (equivalent to 1.5 to 2.5 grams of dried mushrooms). This is the usual dose for those who desire the full psychedelic effects of magic mushrooms.
This dosage can result in changes in perception, mood enhancement, increased creativity, and a sense of unity with the environment. Mild visual effects might occur, but intense hallucinations are not typical. The experience is akin to stepping into a vivid dream world where reality merges with a captivating variety of visual and auditory sensations.
These euphoric feelings often express themselves through dance, gentle movements, or simply surrendering to the psychedelic rhythm. The experience generally lasts from 4 to 8 hours. At this level, visual distortions may become more pronounced, with patterns seeming to move and transform, and your surroundings appearing to pulsate with energy.
While this dosage is manageable, it requires a safe environment and a positive mindset. It offers a journey of awe and wonder, inspiring exploration of consciousness. with a sense of cautious optimism.
- Enhanced color perception.
- Visual distortions, such as objects appearing to shift or “breathe”.
- Experiencing synesthesia, like “seeing sounds” or “hearing colors”.
- A profound appreciation for music.
- Spontaneous bouts of laughter.
- Altered tactile sensations.
- Engagement in self-reflection.
- Feelings of euphoria.
- Distortions in the perception of time.
- Increased heart rate and blood pressure.
Products Offered by Magic Mushroom Stores
Magic mushroom stores offer an array of products infused with psilocybin. These stores present various options including dried mushrooms, edibles, capsules, and beverages, among others. Dried mushrooms are particularly favored.
Health Canada recognizes over 200 types of magic mushrooms, with Psilocybe cubensis being a commonly sold species. This strain comes in several varieties, providing a wide array of choices for customers, similar to the available options at cannabis dispensaries.
Other Shroom Products:
| Edibles | Food items such as gummies and chocolates that are infused with psilocybin. The dosage is clear as manufacturers indicate the amount per serving. |
| Capsules | These are flavorless and can be seamlessly integrated into your wellness routine. They contain only small amounts for a subtle enhancement of your daily regimen. |
| Beverages | These are similar to edibles, but in a liquid form. They are available in a variety of options including chocolate, coffee, or tea. |
Determining Your Dose at Magic Mushroom Dispensaries
While magic mushrooms are not commonly used as a treatment for depression, Canada has made a progressive step. They have permitted the testing and medical use of psilocybin, a Schedule I substance under the Controlled Drugs and Substances Act, for certain patients battling severe major depressive disorder. This decision could potentially benefit tens of thousands exploring alternative treatment options for anxiety and depression through clinical trials.
Commonly Asked Questions
Can psilocybin be purchased from a What is a medicinal mushroom dispensary?
A medicinal mushroom dispensary typically carries products like Reishi, Turkey Tail, and Lion’s Mane. If you’re curious about exploring the world of mushrooms, an online magic mushroom dispensary might be your ideal destination. These dispensaries carry a wide range of mushroom products, including dried mushrooms and other psychedelic substances.
Is a 25 mg dosage effective in treating depression?
Research is currently being conducted on various psilocybin dosages for depression treatment. Some studies have examined lower dosages, while others have focused on higher amounts of psilocybin. A possible approach could be to begin with a microdose and gradually increase the dosage as required.
Can shrooms be purchased in Toronto?
Online mushroom sellers offer the convenience of shopping from any location in Canada. Regardless of your province or city, these online platforms ensure delivery straight to your doorstep.
What is the most economical product in an online mushroom shop?
Dried mushrooms are often the preferred choice for customers due to the availability of various quantities. The price may fluctuate depending on whether you require a small amount like 1 gram or intend to purchase in bulk. Even though edibles and other products are fairly priced, they might not be as cost-efficient as dried mushrooms.
Can a single dose of shrooms help alleviate depression?
Some studies suggest that a one-time usage could be enough to lessen symptoms of depression. However, it’s important to highlight that these study participants also took part in talk therapy alongside the treatment. This combination of psychedelic therapy and therapeutic sessions seems to yield the most effective results.
About the Author
This article was authored by Charles L. Raison et al.; Jeremy D. Coplan, MD and Dorothy P. Reddy, MD; Albert Garcia-Romeu, Frederick S Barrett, Theresa M Carbonaro, Matthew W Johnson, and Roland R Griffiths; Vince Polito and Richard J. Stevenson, alongside Rebecca Smausz, Joanna Neill, and John Gigg.
Affiliated Institutions:
- Fitchburg’s Usona Institute, Wisconsin
- SUNY Downstate Medical Center in Brooklyn, New York
- Neurogenesis Clinics, based in Brooklyn, New York
- The Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine in Baltimore, MD, USA
- Johns Hopkins University School of Medicine’s Center for Psychedelic and Consciousness Research in Baltimore, MD, USA
- The Department of Neuroscience at Johns Hopkins University School of Medicine in Baltimore, MD, USA
- The Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine, USA, Baltimore
- Macquarie University’s Department of Cognitive Science in Sydney, Australia
- Department of Psychology at Macquarie University, Sydney, Australia
- The Division of Neuroscience and Experimental Psychology in the Faculty of Biology, Medicine and Health at The University of Manchester, UK, Manchester
- The Division of Pharmacy and Optometry within the Faculty of Biology, Medicine and Health at The University of Manchester, Manchester, UK
- Medical Psychedelics Working Group, in association with Drug Science, UK
